AVIR: Atea Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 282.95
Enterprise Value ($M) 184.49
Book Value ($M) 458.52
Book Value / Share 5.43
Price / Book 0.62
NCAV ($M) 454.47
NCAV / Share 5.38
Price / NCAV 0.62

Profitability (mra)
Return on Invested Capital (ROIC) -0.38
Return on Assets (ROA) -0.29
Return on Equity (ROE) -0.30

Liquidity (mrq)
Quick Ratio 19.33
Current Ratio 19.33

Balance Sheet (mrq) ($M)
Current Assets 486.91
Assets 490.96
Liabilities 32.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
3 days ago 13G/A Fmr Llc 7.84 23.69
02-14 13G/A EcoR1 Capital, LLC 8.40 13.11
02-13 13G/A Sommadossi Jean-Pierre 9.60 9.20
02-13 13G/A Vanguard Group Inc 5.51 -24.47
02-07 13G BML Investment Partners, L.P. 6.70 33.90
01-24 13G/A BlackRock Inc. 11.30 6.86
11-28 13D/A Tang Capital Partners Lp 4.80 33.27

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 69,961 164,131 42.63
2024-11-13 22,962 136,077 16.87
2024-11-12 30,875 186,622 16.54
2024-11-11 22,442 218,130 10.29

(click for more detail)

Similar Companies
ASMB – Assembly Biosciences, Inc. ATHA – Athira Pharma, Inc.
ATRA – Atara Biotherapeutics, Inc. AVXL – Anavex Life Sciences Corp.
BBIO – BridgeBio Pharma, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Aviragen Therapeutics